June 10, 2024 Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug This post was originally published on this siteThe modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.